Atopic Dermatitis

In this episode, Renata Block, DMSCc, MMS, PA-C, discusses the new ICD-10 code for topical steroid withdrawal with Kelly Barta, the president and executive director of the International Topical Steroid Awareness Network.

Real-world TARGET-DERM data show switching to upadacitinib boosts skin clearance, itch relief and quality of life for tough atopic dermatitis.

IEC modified Delphi process establishes standardized treatment targets for atopic dermatitis

New phase 3 data show oral TYK2 inhibitor soficitinib improves moderate-to-severe atopic dermatitis, easing itch with no new safety signals.

TRAPEDS-1 met its primary pharmacokinetic objective in children aged 6 to 11 years with moderate to severe atopic dermatitis, with no new safety signals over up to 172 weeks of tralokinumab treatment.

The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed interim phase 2 trial findings showing GX-03 efficacy across a broader range of EASI severity scores in atopic dermatitis.

Turn Therapeutics finalized its stage 2 trial design after interim data showed clinically meaningful GX-03 efficacy in patients with baseline EASI scores as low as 1.1.

Roman Bronfenbrener, MD, discusses how AI-generated patient diagnoses are reshaping dermatology visits and creating new challenges.

Evommune's EVO756 failed to meet the primary end point in a phase 2b trial for chronic spontaneous urticaria, prompting the company to discontinue development for the indication while continuing studies in atopic dermatitis.

Raj Chovatiya, MD, PhD, MSCI, co-chair of RAD 2026, highlighted new AD science, type 2 inflammation insights, and emerging therapies—helping clinicians translate immunology advances into better patient care.

Kymera Therapeutics finished enrollment in its phase 2b BROADEN2 trial of KT-621 nearly six months early, moving up topline AD data to year-end 2026.

Expert guidance from RAD 2026 dispels eczema diet myths, urging symptom-based allergy testing and whole-patient atopic dermatitis care with practical skin, sleep, and lifestyle strategies.

Discover how JAK inhibitors reshape AD care with rapid relief, smart safety screening, and emerging personalized strategies that guide real-world treatment choices.

AbbVie’s $10.9B deal adds Apogee’s long-acting IL-13 and TSLP antibodies to its portfolio, aiming for less frequent dosing in atopic dermatitis and asthma.

At RAD 2026, Peter Lio, MD, discussed shared decision-making strategies and emerging microbiome-targeted therapies for atopic dermatitis.

Peter Lio, MD, explains how shared decision-making and newer nonsteroidal topicals and systemic options are reshaping pediatric eczema care, easing steroid worries.

Mona Shahriari, MD, FAAD, urges viewing AD as systemic, guiding earlier personalized systemic therapy while optimizing topicals and shared decision-making

David Rosmarin, MD, reviewed the heterogeneous nature of chronic hand eczema, areas of unmet need in atopic dermatitis treatment, and emerging systemic options in the vitiligo pipeline at RAD 2026.

Adam Friedman, MD, discusses dysbiosis and immune dysfunction in atopic dermatitis and the impact on bacterial and viral infections.

Mona Shahriari, MD, FAAD, shares expert insights on tailoring atopic dermatitis care, from IL‑13 biologics to promising OX40 drugs that may modify disease long term.

At RAD 2026, David Rosmarin, MD, discussed the unmet need in chronic hand eczema, emerging pipeline agents, and his approach to evaluating clinical trial data.

Explore evolving pediatric atopic dermatitis care: personalized, stepwise therapy, early-infant treatment gaps, growth monitoring, and expanding nonsteroidal options promising better outcomes.

Drawing parallels to diabetes and hypertension, Adam Friedman, MD, invokes the dangerous side effect of doing nothing in reframing treatment strategies.

Adam Friedman, MD, maps the AD comorbidity spectrum, from T2-driven diseases to sleep-related indirect consequences, and discusses clinical implications.